【Diamond Investment】Announcement of Changes in Shareholdings and Fair Value of Investment Targets, and Net Asset Value per Share, Cash and Cash Equivalents Balance

1. Date of Event: 115/07/07

2. Company Name: Diamond Biotech Investment Co., Ltd.

3. Relationship with Company (please enter本公司or 子公司):本公司

4. Cross-shareholding Ratio: Not applicable

5. Reason for Announcement: In accordance with the letter No. 1121802934 issued by Taiwan Stock Exchange Corporation on June 29, 2023, the company is required to disclose monthly changes in shareholdings and fair value of all investment targets, as well as net asset value per share, cash and cash equivalents balance.

6. Response Measures: (1) The changes in shareholdings and fair value of investment targets held by the company in June 2026 are as follows:

(Unit: shares; thousand NTD) June 115 May 115 Change in Change in Company Name Holdings Holdings Holdings Fair Value -------------- ----------- ----------- ---------- ---------- Glycos 30,869,000 30,869,000 - 2,112,674 Biomedical (Co.) Ltd.

StemCyte 32,937,150 32,793,150 144,000 (7,196) Biotech (Co.) Ltd. (StemCyte International Ltd.)

Theia Medical 9,042,648 9,042,648 - 6,546 Technology Co. Ltd.

Hsin Yao 6,696,209 6,696,209 - 36,762 Biomedical (Co.) Ltd.

EyeYon 59,018 59,018 - (1,357) Medical Ltd.

Tiante Tai 7,900,000 7,900,000 - (237) Agriculture Biotech (Co.) Ltd.

Kendall N/A N/A N/A 8,892 Capital Partners I, L.P

Bilayer 915,540 915,540 - 9 Therapeutics, Inc.

U-All 5,331,428 5,331,428 - 0 (Co.) Ltd.

Rejuvenate Bio 1,498,801 N/A 1,498,801 39,808 Inc.

Syncell Inc. 10,367,059 10,367,059 - 3,318

Diamond No.1 200,000,000 200,000,000 - 2,504 Investment (Co.) Ltd.

Diamond High 200,000,000 200,000,000 - 7,496 Tech Investment (Co.) Ltd. ----------------------------------------------------------------------- Total 2,209,219 ===========

(2) The company's net asset value per share and cash and cash equivalents balance are as follows:

Date Net Asset Value per Share (NTD) Cash and Cash Equivalents (thousand NTD) ------------- ---------------------------------- ---------------------------------------- June 30, 115 14.41 2,533,476

7. Other Matters to be Disclosed (If the entity involved in the event or resolution is a publicly listed company, this material information also qualifies as a significant matter under Article 7, Paragraph 9 of the Enforcement Rules of the Securities and Exchange Act, which may materially affect shareholders' rights or securities prices): The company's primary investment targets are biotechnology-related stocks, whose prices and fair values are highly sensitive to R&D outcomes, leading to significant volatility. Therefore, if the fair value declines during the year, the company's operating income may become negative.